コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ts with multiple endocrine neoplasia type 2 (MEN 2).
2 ndromes multiple endocrine neoplasia type 2 (MEN 2).
3 d treatment they had before the diagnosis of MEN 2.
4 HD 2 to 63 years before being diagnosed with MEN 2.
5 mptoms 1 to 24 years before the diagnosis of MEN 2.
6 ochromocytoma tumorigenesis in patients with MEN 2.
7 n patients with von Hippel-Lindau disease or MEN-2.
8 d randomisation (via minimisation) allocated men 2:1:1:1 to standard of care only (SOC-only; control)
11 x effect for bladder cancer (OR for women vs men 2.31, 95% CI 1.98-2.69) and no apparent ethnic group
14 right ventricular muscle mass (women, 1.58; men 2.45; P=0.001), poorer peak oxygen uptake (women, -1
16 ntervals (CI) for sarcopenia were higher for men 2.82 (2.22-3.57) and those with higher %BF 1.08 (1.0
17 sion of multiple endocrine neoplasia type 2 (MEN 2), a dominantly inherited cancer predisposition.
18 T cause multiple endocrine neoplasia type 2 (MEN 2), an inherited cancer syndrome characterized by me
22 jority of cases of inherited cancer syndrome MEN 2, and inactivating mutations in some cases of domin
23 ermline mutations in RET are responsible for MEN 2 but the precise pathogenetic mechanisms of tumorig
24 to treat human papillary thyroid carcinomas, MEN 2 disease, as well as the sporadic cancers relevant
26 eavy alcohol consumption (women 1 drink/day; men 2 drinks/day; one drink contains 14 g of ethanol in
27 The identification of RET mutations in most MEN 2 families (95%) has translated into improved care f
28 esting is considered the standard of care in MEN 2 families because clinical decisions are made based
32 ease or multiple endocrine neoplasia type 2 (MEN-2), is hindered by the inadequate sensitivity of com
33 RET lead to tumor formation in patients with MEN 2, it is not understood why only selected cells deve
35 curs in multiple endocrine neoplasia type 2 (MEN 2) (MIM No 171400), von Hippel-Lindau (VHL) disease
37 of patients with no evidence of VHL disease, MEN 2 or NF1: Group A, eight kindreds with familial phae
39 n GDNF in 28 sporadic phaeochromocytomas, 12 MEN 2 phaeochromocytomas and five VHL phaeochromocytomas
41 omocytomas from five unrelated patients with MEN 2 showed either duplication of the mutant RET allele
46 called multiple endocrine neoplasia type 2 (MEN 2) that includes medullary thyroid carcinoma (MTC).
47 (VHL), multiple endocrine neoplasia type 2 (MEN 2), the newly delineated phaeochromocytoma-paragangl
51 on Hippel-Lindau disease and 9 patients with MEN-2 who had histologically verified pheochromocytomas
52 0 patients with von Hippel-Lindau disease or MEN-2 who had no radiologic evidence of pheochromocytoma